<!DOCTYPE html>
<html>
<head>
<meta charset="utf-8"/>
<meta content="width=device-width, initial-scale=1.0" name="viewport"/>
<link href="../../../webpages.css" rel="stylesheet"/>
</head>
<body>
<div class="banner">
<div class="banner-content">
<h1>DermpathNet</h1>
</div>
</div>
<nav>
<a href="../../../index.html" target="_blank">
<text type="button">Home</text>
</a>
<a href="../../../browser-page-317.html" target="_blank">
<text type="button">Browse</text>
</a>
<a href="../../../download-page.html" target="_blank">
<text type="button">Downloads</text>
</a>
<a href="../../../contact-us.html" target="_blank">
<text type="button">About</text>
</a>
</nav>
<footer class="site-footer">
<p>@2024 New York University Grossman School of Medicine, Weill Cornell Medicine</p>
<!--<p>Privacy Policy | Terms of Service | Cookie Policy</p>-->
</footer>
<title>A comprehensive evaluation of pathogenic mutations in primary cutaneous melanomas, including the identification of novel loss-of-function variants.-DermPath</title>
<div class="content-container"> <div class="figures-container"> <div class="image-side"> <img alt="A comprehensive evaluation of pathogenic mutations in primary cutaneous melanomas, including the identification of novel loss-of-function variants." class="clickable-image" src="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6863855/bin/41598_2019_53636_Fig2_HTML.jpg"/> </div> <div class="text-side"> <h1>A comprehensive evaluation of pathogenic mutations in primary cutaneous melanomas, including the identification of novel loss-of-function variants.</h1> <p>Representative examples for the ARID1A and p53 staining. (A) weak and focally strong ARID1A positivity in a case with a novel benign p.(E1779G) missense mutation, 200x magnification; (B) absence of ARID1A staining in a melanoma with a novel nonsense pathogenic mutation p.(R1721X), 200×; (C) wild-type p53 staining with an aberrant clone with nuclear p53 overexpression in a melanoma with detected novel splice TP53 mutation c.75-1G&gt;T, affecting the consensus splice site in intron 2, 100×; (D) aberrant p53 staining with diffuse strong nuclear expression in a melanoma that developed pathogenic missense TP53 mutation p.(G245D), 100×.</p> <p>PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/31745173/" target="_blank">31745173</a></p><p>Type: Premalignant/Malignant, Category: Melanocytic</p>
</div> </div></div></body></html>